Sponsor: NCCTG
Sponsor Study ID: CCTG-PR26
Study Title: A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH)
CTO #: 104186
NCT Number: NCT06592924
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: To compare overall survival in participants with mCSPC who are receiving standard of care ADT (between 6-12 months exposure) + ARPI and have suboptimal PSA response with those who recieve standard of care ADT + ARPI plus docetaxel chemotherapy.